Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci

NCT02623413

Vancomycin (Glycopeptide) Resistant Enterococcus (VRE) Cancer

UNKNOWN

Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures

NCT00475891

Isolate Linezolid

COMPLETED

The Epidemiology of Infection With Vancomycin-Resistant Enterococci

NCT00018434

Infection

COMPLETED

Vancomycin Resistant Enterococci in Patients Awaiting Liver Transplantation at the University of Michigan: Prevalence, Risk Factors, Natural History and Outcome of Colonization

NCT00005667

Liver Diseases

UNKNOWN

Clinical Trial to Reduce Antibiotic Resistance in European Intensive Cares

NCT00976638

Hospital Acquired Infections

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gram-Positive Bacterial Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Piperacillin/tazobactam and other β-lactam/β-lactamase

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients admitted to or transferred to the SICU.
* Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
* Provide written informed consent

Exclusion Criteria

* Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
* Females who are pregnant and breast feeding
* Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
* Those who have already been participating other clinical study related with antibiotics.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No